Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

NCT04687514 · Completed

Last updated 2026-05-28

This clinical trial is testing whether glucagon-like peptide-1 analogs, a type of medication, affect sexual functioning in people with sexual dysfunction.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind basic-science study

Participants 26 people

Who can join Ages 18–50 · male only Healthy volunteers accepted.

Timeline Started 2021-05 · est. completion 2022-09

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT04687514 ↗

Description as written by the study sponsor.

This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy men.

Treatments tested

Dulaglutide Drug

Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
Placebo Drug

Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.

Main thing measured	Change in sexual functioning, assessed with the German version of the Massachusetts General Hospital - Sexual Functioning Questionnaire (MGH-SFQ).
Sponsor	University Hospital, Basel, Switzerland
Conditions studied	Sexual Functioning
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04687514 ↗